Mixed-lineage leukemia (MLL) fuses with a variety of partners to produce a functionally altered MLL complex that is not expressed in normal cells, which transforms normal hematopoietic progenitors into leukemia cells. Because more than 80 fusion partners have been identified to date, the molecular functions of MLL fusion protein complexes appear diverse. However, over the past decade, the common functions utilized for leukemic transformation have begun to be elucidated. It appears that most (if not all) MLL fusion protein complexes utilize the AF4/ENL/P-TEFb and DOT1L complexes to some extent. Based on an understanding of the underlying molecular mechanisms, several molecular targeting drugs are being developed, opening paths to novel therapies. Here, we review the recent progress made in identifying the molecular functions of various MLL fusions and categorize the numerous fusion partners into several functionally-distinct groups to help discern commonalities and differences among various MLL fusion protein complexes.

中文翻译：

---

常见和非典型MLL融合蛋白复合物的分子功能。

混合谱系白血病（MLL）与多种配偶体融合，产生功能改变的MLL复合物，该复合物在正常细胞中不表达，从而将正常的造血祖细胞转化为白血病细胞。迄今为止，由于已鉴定出80多个融合伴侣，因此MLL融合蛋白复合物的分子功能似乎各不相同。但是，在过去的十年中，已经阐明了用于白血病转化的共同功能。似乎大多数（如果不是全部）MLL融合蛋白复合物在一定程度上利用了AF4 / ENL / P-TEFb和DOT1L复合物。基于对潜在分子机制的了解，正在开发几种分子靶向药物，为新疗法开辟了道路。这里，